logo BDSP

Base documentaire

  1. Racial differences in responses to therapy with interferon in chronic hepatitis C.

    Article - En anglais

    The likelihood of a sustained response to a course of interferon in patients with chronic hepatitis C correlates with several clinical and viral factors, including age, viral genotype and initial levels of hepatitis C virus (HCV) RNA in serum.

    The role of race and ethnicity has not been assessed.

    We evaluated the association of race with response to interferon in a large randomized, controlled trial using either consensus interferon (9 mug) or interferon alfa-2b (3 million units) given three times weekly for 24 weeks.

    African-American patients participating in the study were similar to white patients in mean age (43 vs. 42 years) and baseline levels of HCV RNA (3.6 vs. 3.0 million copies/mL) but had lower rates of cirrhosis (5% vs. 12%) and more frequently had viral genotype 1 (88% vs. 66% : P=004).

    Most strikingly, the rates of end-of-treatment and sustained virological responses were lower among the 40 African-American patients (5% and 2%) than among the 380 white patients (33% and 12%) (P=04 and. 07).

    Rates of response among Hispanic and Asian-American patients were not statistically different than non-Hispanic white patients.

    Median viral levels decreased by week 24 of therapy by 2.5 logs in white patients (from 3.0 to 0.012 million copies/mL) but by only 0.5 logs among African-American patients (from 3.6 to 1.8 million copies/mL). (...)

    Mots-clés Pascal : Hépatite virale C, Virose, Infection, Chronique, Essai thérapeutique contrôlé, Interféron, Réponse, Critère, Ethnie, Etude cohorte, Randomisation, Etats Unis, Amérique du Nord, Amérique, Japon, Asie, Homme, Evaluation, Appareil digestif pathologie, Foie pathologie, Antiviral, Immunomodulateur, Organisation santé, Antirétroviral

    Mots-clés Pascal anglais : Viral hepatitis C, Viral disease, Infection, Chronic, Controlled therapeutic trial, Interferon, Response, Criterion, Ethnic group, Cohort study, Randomization, United States, North America, America, Japan, Asia, Human, Evaluation, Digestive diseases, Hepatic disease, Antiviral, Immunomodulator, Public health organization

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0476495

    Code Inist : 002B05C02G. Création : 22/03/2000.